FORMULATION DEVELOPMENT AND EVALUATION OF SUSTAIN RELEASE TABLET OF VANLAFAXINE

Highly water soluble compounds found in antidepressants like Venlafaxine must be packaged into delivery systems in the form of pellets in order to provide a constant and prolonged release. Self-observation, FTIR analysis, and DSC drug profiling were used in the prefformulation investigation of the drug excipients. Both medications had an analytical method (UV) established for them in various media. Extrusion and spheronization were regulated processes used to create drug-loaded pellets, which were then covered in a controlled-release coating and compacted into tablets. For the created system, physicochemical, functional, and structural characterisation were carried out. Results of prefformulation tests showed that particular medications were suitable for oral solid dosage forms. New UV techniques demonstrated required linearity with little noise. Drugs and a few excipients were discovered to be compatible. Pellet optimization was aided by the use of QbD tools such as risk assessment, screening design, and DoE. 3.3%, 26.8%, 51.9%, 74.1%, and 91.4% of the drug was released at 2, 4, 8, 12, and 20 hours from an optimised pallet filled with VEN, and 4.3%, 26.5%, 57.2%, 78.7%, and 93.3% from compressed tablets loaded with VEN, respectively. The created multiparticulate pellets compressed as tablet system for the chosen medicament yielded the desired drug release profile. So, if BCS class I medicines are added to a designed system, consistent blood plasma concentration can be anticipated.